Noninvasive LED light therapy shows long-term safety in early cataract follow-up

Edinburgh Biosciences has reported encouraging early outcomes from a structured long-term safety and performance follow-up phase of its clinical trial program for Revisyon, a non-invasive, LED light-based therapy designed for patients with vision affected by cataracts, the company announced in their press release.

Revisyon is described as a device-led therapy that applies specific wavelengths of low-level LED light to the crystalline lens through a non-invasive, in-clinic procedure. The technology does not use laser energy and has been developed to work with the eye’s natural structures at the molecular level without surgery, with the aim of supporting lens clarity. Ophthalmologists in clinical practice, not hospitals, will deliver the therapy, the company explained.

The just-completed evaluation found no adverse events, with visual function remaining stable after treatment. Patients also reported positive feedback on their therapeutic experience.

The company views this technology as shift in treatment, not as an improvement on existing surgeries, in that an intervention that addresses cataracts will happen earlier, in primary care settings, with a completely different technologic approach, they explained.

The clinical trials were completed in early 2025, and the follow-up study assessed the durability of the safety and treatment effect over time. Participants were monitored for an average of 20 months after completing treatment, with the longest follow-up period out to 36 months. Detailed clinical findings are scheduled for submission to a peer-reviewed journal in the first half of 2026.

Because the current cataract care is surgical intervention, which is typically offered only after vision loss has progressed to a significant level and often following extended waiting times, Revisyon was developed in response to this unmet clinical need for earlier intervention within routine eye-care settings. The therapy is intended to support individuals experiencing early vision changes and to complement existing cataract care pathways rather than replace them, according to the press release.

By extending access to care outside hospitals, the technology has the potential to ease pressure on secondary care services while improving convenience and accessibility for patients.

Alok Machchhar, Chief Commercial Officer at Edinburgh Biosciences, commented on the completed follow-up phase, “The completion of the long-term safety and performance evaluation marks an important milestone in Revisyon’s development and brings us closer to potential launch. The study has helped us better understand how patients experience the treatment beyond the initial clinical setting.”

He continued, “The positive early feedback is encouraging and highlights the importance of exploring alternative approaches to cataract-related vision changes. Our priority remains to build a robust clinical evidence base and to work responsibly within established care pathways as we prepare for the next stages of development.”

Edinburgh Biosciences expects the full clinical dataset, incorporating trial outcomes and long-term follow-up results, to be submitted for peer-reviewed publication in the first half of 2026. Any future availability of Revisyon will remain subject to regulatory approval.